The invention refers to the use of an engineered 'Clustered Regularly Interspersed Short Palindromic Repeat (CRISPR)-CRISPR associated (Cas)’ (CRISPR-Cas) technology targeting a sequence mutated at one or more loci in the genome of a given eukaryotic cell
The present invention represents an in vitro implementable method and related kit for assessing the response to immune tolerance restoration therapy by evaluating the expression of specific microRNAs (miRNAs) as biomarkers of residual beta-cell function.
The present invention consists of an electromechanical stimulation system, and related wearable device, generating and transmitting mechanical vibrations to the bone processes near a user's ear.
This invention makes it possible to study in depth the phenomena involved in the ultrasonic stimulation of living materials and cells, thus paving the way for the optimisation of these stimulation processes in numerous areas
The research focus has been on developing a method and an apparatus for in vitro three-dimensional cell co-culture
The invention relates to the use of beta-blocking compounds, in particular the antagonist of ?3 adrenoceptor (?3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer.
The invention is represented by a mixture of molecules, called A_ATROFI, capable of regulating the balance between protein synthesis and its degradation in skeletal muscle cells.
The innovative method to diagnose uroperitoneum involves determining the concentration of a biomarker, Uromodulin, in a sample taken from abdominal drainage.
The invention describes a method for the diagnosis of neurodegenerative diseases based on the measurement, in a peripheral blood sample, of ?-synuclein heteromeric complexes with ?-amyloid or Tau protein.
The patented invention relates to techniques for fabricating composite polymer microstructures and not applicable to the field of Textile Engineering.
